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Altered Levels of Serum Haptoglobin and Apo A-I in Schizophrenia
(Perubahan Paras Haptoglobin dan Apo A-I Serum dalam Skizofrenia)
TZE JEN CHOW & HAN CHERN LOH* 
ABSTRACT
Schizophrenia is a debilitating psychiatric syndrome that affects 1% of the world’s population. Abnormalities in immune 
functions and role of inflammatory markers have been widely described in schizophrenia. With the alarming high 
prevalence, this study aims to investigate the association of acute phase proteins with schizophrenia. We investigated the 
serum proteome of 20 schizophrenic patients and 20 healthy controls using two-dimensional gel electrophoresis and mass 
spectrometry. The spots were analysed using Image Master 2D Platinum software. In total, we have detected 774 protein 
spots in human serum and found that three of them showed altered changes in schizophrenic patients, as compared to 
healthy controls. Among these acute phase proteins, haptoglobin (p = 0.003) and two isoforms of apolipoprotein A-I (p 
= 0.004, p = 0.003) were found to be significantly decreased in patients, as compared to controls. Our findings support 
the hypothesis that inflammatory response system is linked to the pathophysiology of schizophrenia.
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ABSTRAK
Skizofrenia adalah sejenis penyakit psikiatrik yang melesukan dan mempengaruhi 1% daripada penduduk sedunia. 
Ketidaknormalan dalam fungsi pertahanan dan peranan sebagai penanda keradangan semakin meluas dihuraikan dalam 
skizofrenia. Dengan bahaya yang berpeluang tinggi dijangkiti, kajian ini bertujuan untuk menyelidik hubungan protein 
fasa tajam dengan skizofrenia. Kami mengkaji proteom serum 20 pesakit skizofrenia dan 20 kawalan yang sihat dengan 
menggunakan gel elektroforesis dua-dimensi dan spektrometri jisim. Tanda-tanda dianalisiskan dengan menggunakan 
perisian ImageMaster 2D Platinum. Secara kesuluruhannya, kami telah mengesan 774 tanda protein dalam serum 
manusia dan mendapati tiga tanda menunjukkan perubahan dalam pesakit skizofrenia berbandingkan dengan kawalan 
yang sihat. Di kalangan tiga protein fasa tajam ini, haptoglobin (p = 0.003) dan dua isofom apolipoprotein A-I (p = 
0.004, p = 0.003) didapati menurun secara nyata dalam pesakit berbanding dengan kawalan. Keputusan ini menyokong 
andaian bahawa sistem tindak balas keradangan adalah berhubung kepada patofisiologi skizofrenia.
Kata kunci: Apolipoprotein A-I; haptoglobin; skizofrenia
INTRODUCTION
Schizophrenia (SCZ) is a debilitating mental disorder 
that affects approximately 1% of the world’s population 
(Schwarz & Bahn 2008). From 2003 to 2005, there were 
7151 cases that had been registered in Malaysia (National 
Mental Health Registry 2006) and 1.8% of the total suicide 
death in year 2007 was caused by SCZ (Hayati et al. 2008). 
In spite of the high prevalence and morbidity, its etiology 
remains unknown and usually associated with various factors 
including genetic inheritance, oxidative stress and immune 
alterations (Morera et al. 2007; Othmen et al. 2008). 
 Acute phase proteins (APPs) are markers of 
inflammation, whose plasma level alters with the activation 
of inflammatory response system (Gaur et al. 2008). The 
importance of APPs as biomarker have been reported in 
diseases such as cancer (Chen et al. 2009), depression 
and Alzheimer’s disease (AD) (Harr et al. 1996). During 
abnormal immune reactions, inflammatory cytokines 
stimulates the production of APPs such as haptoglobin, 
apolipoproteins and macroglobulin to activate the 
complement system (Greco et al. 2009). In the central 
nervous system, this inflammatory process might impair 
the blood-brain barrier and cause damage to the brain (Yang 
et al. 2006). 
 Abnormalities in the immune function and the role 
of inflammatory markers have been widely described in 
SCZ (Maes et al. 1997; Morera et al. 2007). Alterations in 
the plasma APP levels of schizophrenic patients suggested 
possible role of the proteins in the pathophysiology of SCZ 
(Wan et al. 2007). Previous researches on APPs in SCZ (Table 
1) mainly focused on haptoglobin (Hp), apolipoprotein 
(Apo) A-I, Apo A-IV and Apo D (Rothermundt et al. 
2001). 
 Hp is a free haemoglobin-binding protein where 
its low level is associated with hemolysis, allergy and 
hepatocellular disorders (Sadrzadeh & Bozorgmehr 2004). 
In SCZ, Hp plays a role in the oxidative injury of the central 
nervous system (CNS) (Wan et al. 2007), in which increased 
oxidative stress was hypothesised in the etiology of SCZ 
(Kunz et al. 2008; Othmen et al. 2008). 
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       Apolipoproteins have been widely studied in SCZ. Apo 
A-I is synthesised predominantly in the liver and intestine, 
involving in the transport of cholesterol from tissues to 
the liver (Rottman et al. 1991). In humans, the gene of 
Apo A-I is found to overlap with SCZ susceptibility loci 
on chromosome 11q23 (Arinami et al. 1990), and there is 
accumulating evidence indicating that down-regulation 
Apo A-I protein is often linked with the pathology of 
SCZ (Huang et al. 2008; La et al. 2007). Based on the 
immune-inflammation hypothesis, it has been shown that 
schizophrenic patients treated with the combination of 
antipsychotics and lipophilic anti-inflammatories would 
lead to down-regulation of immune response in the CNS 
(Muller et al. 2002). Thus, the aim of this study was to 
investigate the association of APPs with SCZ.
MATERIALS AND METHODS
SUBJECT SELECTION
The sample population consisted of 20 controls with no 
history of psychiatric disorders (10 male and 10 female) and 
20 schizophrenic subjects (10 male and 10 female) recruited 
from Bahagia Ulu Kinta Hospital, Perak, Malaysia. This 
study was approved by the Medical Research and Ethics 
Committee, Ministry of Health, Malaysia. Written consents 
were obtained from healthy subjects before participation 
in the study. The diagnoses of schizophrenic subjects were 
done according to the Mini International Neuropsychiatric 
Interview (M.I.N.I.), English Version 5.0.0 (Sheehan et al. 
1998), by treating psychiatrists. Only patients of paranoid 
subtype were selected. Both patients and controls were 
residents of Malaysia, age ranging from 30 to 45 years 
(patient mean age = 38.55±5.33; control mean age = 
37.00±4.68). 
 In total, 10 mL of peripheral blood were ejected from 
subjects into 10 mL vacutainer (Becton, Dickinson & 
Company, USA) for serum collection. The blood samples 
were span down at 4000 rpm for 5 min at 4oC, and serum 
at the supernatant layer was collected and stored at -80oC. 
Total protein content was determined by Bradford assay. 
TWO-DIMENSIONAL GEL ELECTROPHORESIS (2-DE)
First dimension separation by IEF was performed using 
Ettan IPGphor 3 system (GE Healthcare, USA), followed by 
SDS-PAGE using Hoefer SE 600 Ruby (GE Healthcare, USA) 
for second dimension separation. In total, 50 μg of serum 
protein was rehydrated overnight at room temperature with 
rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 
20 mM DTT, and 0.5% IPG buffer) to a final volume of 
250 μL on 13 cm, pH 4 – 7 Immobiline DryStrip gels 
(GE Healthcare, USA). IEF was performed at 500V for 
1 h, ramped up to 1000V for 1 h and then maintained at 
8000V for 2 h. The strip was equilibrated (6 M Urea, 50 
mM Tris–HCl pH 8.8, 30% glycerol, 2% SDS) with 10 mg/
mL DTT, followed by 25 mg/mL iodoacetamide. Second 
dimension was performed on 12.5% SDS-polyacrylamide 
gel (18 × 16 cm2, 1 mm thickness), and stained using 
PlusOne Silver Staining Kit (GE Healthcare, USA). 
SPOT ANALYSIS
ImageMaster 2-D Platinum software (GE Healthcare, 
USA) was used for the analysis of the gels. After spot 
detection and gel matching, differently expressed spots 
were identified. For peptide mass fingerprinting (PMF), 
a preparative gel was done and stained using Coomassie 
blue R-250, where spots were excised and sent for trypsin 
digestion and MALDI-ToF/ToF MS. The database search 
was done using Mascot 1.9 (www.matrixscience.com) 
TABLE 1. Biomarkers for SCZ identified by proteomics methods using human samples.
Protein marker Sample type Observations References
Apo A-I brain tissue
CSF
red blood cells
plasma
decreased
decreased
decreased
decreased
Huang et al. (2008)
Huang et al. (2008)
Huang et al. (2008)
Huang et al. (2008); La et al. (2007); Yang et al. (2006) 
Apo A-IV CSF
plasma
decreased
increased
Jiang et al. (2003)
Yang et al. (2006)
Apo D plasma
plasma
brain tissue
increased
decreased
increased 
Mahadik et al. (2002)
Thomas et al. (2001)
Thomas et al. (2001)
Apo E brain tissue increased Dean et al. (2003)
Haptoglobin plasma increased Maes et al. (1997); Wan et al. (2007); Wong et al. (1996); 
Seal & Eist (1966); Yang et al. (2006)
α1-antitrypsin plasma increased Wong et al. (1996); Yang et al. (2006) 
Complement factor B plasma increased Yang et al. (2006)
Transthyretin CSF
plasma
no relationship
decreased
Huang et al. (2007)
Yang et al. (2006)
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where Mascot scores greater than 82 are significant (p 
< 0.05) for PMF search. Data were presented as mean ± 
standard deviation. Differences between control and patient 
were assessed using one-way analysis of variance where 
p-value < 0.01 was considered statistically significant.
RESULTS
Human serum proteins were quantified and identified 
from 2-DE gels using the ImageMaster 2-D Platinum 
software and MALDI-ToF/ToF MS. A total of 774 protein 
spots were detected by the software on silver-stained gels. 
To fulfil the acceptable criteria for disease biomarkers in 
differential display techniques, only protein spots with 
expression levels of two-fold variances were selected 
(Yang et al. 2006). A comparison of the 2-DE gels of 
patients’ serum with those of healthy controls indicated 
that some spots were significantly varied. Three clear 
protein spots were identified using the PMF method of 
MALDI-ToF/ToF MS (Figure 1). Table 2 lists the Swiss-
Prot accession numbers and full names of the protein 
spots, as well as their mascot score, molecular mass, 
pI values, expectation level, and protein amino acid 
sequence coverage by matching peptides. The expression 
levels and fold-change of the proteins are listed in Table 
3. The expression of Hp (spot 1) in controls increased 
dramatically by 5.64-fold compared to that of patients. 
Similarly, Apo A-I-1 (spot 2) and Apo A-I-2 (spot 3) show 
2.24-fold and 4.21-fold higher expression respectively in 
controls. Hp (p = 0.00307) and Apo A-I (p = 0.00365) 
displayed a significant decreased in expression levels in 
the serum of the patients compared to controls. Other 
spots did not show significant quantitative alteration 
between control and patient.
FIGURE 1. Two-DE map of (a) control serum proteins and (b) patient serum proteins. The gel was separated on 18 × 16 cm2 plate 
and silver-stained. The horizontal axis represents the IEF dimension, which stretches from pH 4 to 7. The vertical axis 
represents 12.5% SDS-PAGE gel. Arrows indicate differentially expressed proteins identified by MS
TABLE 2. Mass spectroscopy identification of differentially expressed spots
Spot Protein name Swiss-Prot no. Mascot score MW (kDa) pI Coverage (%) Expect
1 Haptoglobin P00738 391 38.72 6.14 10.0 7.3e-033
2 Apolipoprotein A-I-1 P02647 391 28.06 5.17 71.0 7.3e-033
3 Apolipoprotein A-I-2 P02647 197 28.06 5.27 65.0 1.8e-013
TABLE 3. List of the differentially expressed proteins
Protein name
Protein expression (% volume)
Control Patient p-value Fold change
Haptoglobin 0.91 ± 0.89 0.16 ± 0.13 0.003 5.64
Apolipoprotein A-I-1 2.51 ± 1.60 1.12 ± 0.55 0.004 2.24
Apolipoprotein A-I-2 1.00 ± 0.85 0.24 ± 0.29 0.003 4.21
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DISCUSSION
This study demonstrated the use of proteomic analysis 
of human serum in investigating the pathology of SCZ. In 
this study, we found the down-regulation of both serum 
Hp and Apo A-I levels in patients as compared to healthy 
controls.
 Most investigations that studied the relationship 
between Hp and SCZ have found elevated levels of Hp in 
schizophrenic patients (Wan et al. 2007; Wong et al. 1996). 
However, our results showed significant down-regulation 
of Hp in schizophrenic patients. Difference in sample 
population may contribute to the different results (Wan et al. 
2007), in which our study only selected patients of paranoid 
subtype. Genetic study of the Hp gene suggested that various 
SCZ subtypes are associated with different Hp phenotype 
frequencies. Patients with disorganised, undifferentiated and 
residual subtypes show an excess of the Hp 2-2 phenotype 
but paranoid patients did not fall into the pattern (Maes et 
al. 2001). Although Hp phenotyping is not performed in our 
study, this finding might be related the decreased patient Hp 
level found in the paranoid patients. 
 SCZ patients were shown to have lower carotenoid level 
compared to controls (Chow et al. 2010), where carotenoid 
serves as indicator of overall antioxidant level in human 
(Svilaas et al. 2004; Zhao et al. 2003). Hp has an additional 
role as antioxidant, thus the reduced Hp level in the patient 
serum may be associated with the low antioxidant level seen 
in SCZ (Sadrzadeh & Bozorgmehr 2004).
 Apo A-I serves to decrease cellular reactive oxygen 
species (Robbesyn et al. 2005) and is involved in 
lipoprotein degeneration and regeneration in the CNS (La 
et al. 2007). Yang et al. (2006) reported significant down-
regulation of Apo A-I in SCZ patient. It is noteworthy that 
our study observed a similar trend of significant decreased 
serum Apo A-I in SCZ patients, therefore further confirming 
association of Apo A-I with the pathology of SCZ. Besides 
that, the gene for Apo A-I overlaps with SCZ susceptibility 
chromosome 11, and is also closely linked to the gene for 
Apo A-VI (Karathanasis 1985), where Apo A-VI is widely 
reported in SCZ (Jiang et al. 2003; Yang et al. 2006). 
 Apo A-I is shown to be associated with transthyretin 
(TTR), in which interaction of TTR with high density 
lipoproteins occur through binding with Apo A-I (Sousa 
et al. 2000).  Due to this positive interaction, it is believed 
that Apo A-I and TTR will have the same trend in expression 
level. Decreased levels of TTR are often reported in SCZ 
(Yang et al. 2006), thus Apo A-I is expected to show a 
similar trend, as observed in the patient serum of the current 
study. 
 As a conclusion, it was shown herein the altered 
expressions of Hp and Apo A-I in serum of SCZ patients. Our 
findings suggest decreased levels of Hp and Apo A-I might 
be linked to the disorder and have the potential to become 
biomarkers for SCZ diagnosis. This might give a new pointer 
in the investigation of the pathogenesis of SCZ.
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